AbCellera Biologics (NASDAQ:ABCL) (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.
AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis. Since its founding, the company has announced collaborations with multiple global drug developers to discover antibodies for oncology, infectious diseases, autoimmune disorders and other therapeutic areas. Notably, AbCellera’s platform enabled the rapid identification of bamlanivimab, an antibody developed in collaboration with Eli Lilly for use in COVID-19 treatment.
Founded in 2012 and based on research at the University of British Columbia, AbCellera is headquartered in Vancouver, Canada, and maintains additional research sites and offices in the United States and Europe. The company serves a global client base, supporting both established pharmaceutical companies and emerging biotech ventures. AbCellera’s platform has been applied to more than a dozen target programs, demonstrating flexibility across diverse biological challenges.
Under the leadership of co-founder and Chief Executive Officer Carl Hansen, AbCellera has built a multidisciplinary team of immunologists, data scientists and engineers. The management team continues to advance platform innovations and expand service offerings with the goal of delivering novel antibody therapeutics to patients worldwide.
